Skip to main content
Premium Trial:

Request an Annual Quote

QuantuMDx Gets £15M Investment From Vita Spring IVD Fund for Portable PCR Platform Development

NEW YORK QuantuMDx said Monday that it has obtained a £15 million ($20.3 million) equity investment from Vita Spring IVD Fund, a Hong Kong-based venture capital firm, and will use the proceeds to expand the development of its Q-POC PCR platform for the point of need.

Newcastle upon Tyne, UK-based QuantuMDx said it plans to expand the menu of tests for Q-POC — a portable, sample-to-answer platform — by adding a multiplex respiratory panel and tests for sexually transmitted infections, HPV, and other diseases to the SARS-CoV-2 assay that currently runs on the platform.

The company said it has also entered into discussions for a cooperation agreement with Sansure Biotech, a Changsha, China-based in vitro diagnostic firm, that could accelerate the commercial development of the Q-POC system and cassettes in China and other territories in Southeast Asia, as well as enable the point-of-care test developer to optimize manufacturing and broaden its assay portfolio.

Financial and other terms of the proposed agreement were not disclosed.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.